Cabaletta Bio
Philadelphia
About Cabaletta Bio
Cabaletta Bio is a biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. The company's therapeutic platform produces highly selective autologous chimeric autoantibody receptor (CAAR) T cells that bind and destroy only disease-causing B cells while sparing healthy B cells which are essential for human health. Cabaletta has signed an exclusive licensing agreement and partnership with Penn focused on treating B cell-mediated autoimmune diseases with CAAR T cells. Cabaletta was founded by Dr. Michael Milone, Dr. Aimee Payne and Dr. Steven Nichtberger. Dr. Milone and Dr. Payne are physicians/scientists at Penn and also serve as co-chairs of Cabaletta’s Scientific Advisory Board. The Company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus Vulgaris (mPV). mPV is a rare skin disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Total funding: $310.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2025)
- Ticker: nasdaq:CABA
- Website: cabalettabio.com
- Phone: +1 610 977 2422
Industries & Categories
Biotechnology, Health Care, Medical, Robotics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/cabaletta-bio-98842 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.